Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2026-03-31 00:00:00 ET · period of report 2026-03-30 · accession 0001213900-26-037447 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 2026-03-30 | ORMP | KIDRON NADAV | Pres, CEO, Dir | F - Tax | $3.31 | -44.8K | 3.42M | -1% | -$148.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-30 | F | D | 44,818 | $3.31 | 3,422,243 | D | — | — | (F1) Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share. |